Riboxin, 20 mg/ml 5 ml 10 pcs

Riboxin is a derivative (nucleoside) of purine – a precursor. adenosine triphosphate (ATP). It belongs to the group of drugs that stimulate metabolic processes.

It has antihypoxic and antiarrhythmic action. Increases myocardial energy balance, improves coronary circulation, prevents consequences of intraoperative renal ischemia.

It is directly involved in glucose metabolism and promotes the activation of metabolism in hypoxia and in the absence of ATP. It activates pyruvic acid metabolism, which is necessary for normal tissue respiration, as well as promotes activation of xanthine dehydrogenase.

Stimulates the synthesis of nucleotides and increases the activity of some enzymes of the Krebs cycle. By penetrating into cells it has a positive effect on metabolic processes in the myocardium; it increases strength of heart contractions and promotes more complete myocardial relaxation in diastole, resulting in increase of stroke volume.

The mechanism of antiarrhythmic action is not fully understood. Reduces platelet aggregation, activates tissue regeneration (especially myocardium and gastrointestinal mucosa).

Indications

– complex treatment of myocardial infarction, ischemic heart disease, cardiac rhythm disturbances caused by the use of cardiac glycosides, against myocardiodystrophy after infectious diseases;

– liver diseases (hepatitis, cirrhosis, fatty dystrophy);

– operations on the isolated kidney (as a means of pharmacological protection when the circulation is cut off).

Active ingredient

Composition

1 ml – inosine 20 mg

Ancillary substances:

hexamethylentetramine 2 mg,

sodium hydroxide solution 1 M to pH 7.8-8.6,

water d/i up to 1 ml.

How to take, the dosage

The drug is administered by IV fluids slowly or dropwise (40-60 drops/minute). Treatment starts with administration of 200 mg (10 ml of 20 mg/ml solution) once a day; then, if tolerated well, the dose is increased to 400 mg (20 ml of 20 mg/ml solution) 1-2 times a day. The duration of treatment is 10-15 days.

Stroke administration of the drug is possible in acute cardiac rhythm disturbances in a single dose of 200-400 mg (10-20 ml of 20 mg/ml solution).

For pharmacologic protection of the renal artery undergoing ischemia, riboxin is administered by IV injection in a single dose of 1200 mg (60 ml of 20 mg/ml solution) 5-15 minutes before renal artery clamping and then another 800 mg (40 ml of 20 mg/ml solution) immediately after circulatory recovery.

For intravenous drip infusion, 20 mg/ml solution is diluted in 5% dextrose (glucose) solution or 0.9% sodium chloride solution (up to 250 ml).

Interaction

Immunosuppressants reduce the effectiveness of Riboxin.

When used together with cardiac glycosides, the drug may prevent arrhythmias and increase the positive inotropic effect.

Special Instructions

Riboxin is not used for emergency correction of cardiac abnormalities.

In case of itching and hyperemia of the skin, treatment with the drug should be stopped.

With long-term treatment it is advisable to monitor uric acid concentrations in blood and urine.

Contraindications

– gout;

– hyperuricemia;

– pregnancy;

– lactation period;

– age less than 18 years (efficacy and safety have not been established);

– hypersensitivity to the drug.

With cautiousness:renal insufficiency.

Side effects

Allergic reactions: skin itching, skin hyperemia (the drug should be discontinued).

Rarely: increase of uric acid concentration in the blood, exacerbation of gout (with long-term use).

Overdose

No cases of overdose have been reported at this time.

Similarities